Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2010

View Archived Issues

Clinical development of ChimeriVax-Dengue vaccine updated

EVX-001650 displays antipsychotic activity in mouse models related to schizophrenia

AC-430 confers protection in models of autoimmune and inflammatory conditions

Proof-of-concept secukinumab trial in ankylosing spondylitis meets primary endpoint

Exelixis divulges novel mTORC1 inhibitors

Aveo Pharma advances phase Ib tivozanib/capecitabine combination trial

Orban Biotech receives Qualifying Therapeutic Discovery grant for IBC-VS01 vaccine

Salvat licenses tarafenacin to Kwang Dong Pharma for OAB in South Korea

Morphotek and Hokkaido University join to evaluate amatuximab for pancreatic cancer

Decreased IGF-I levels may correlate with growth defects in newborns with cystic fibrosis

Bristol-Myers Squibb updates pipeline progress for Q3 of 2010

Ipsen Pharma identifies new imidazolidine-2,4-dione derivatives for prostate cancer

Banyu Pharma presents new peptide P518 receptor antagonists

Lumixex launches diagnostic xTAG CYP2D6 Kit in U.S.

Circassia's Toleromune House Dust Mite vaccine shows promise in phase II trial

Genzyme to sell diagnostics business to Sekisui Chemical

Astex Therapeutics claims new fibroblast growth factor receptor inhibitors

Errant Gene Therapeutics receives U.S. federal grant for Thalagen research

Advanced Life Sciences applies for FDA orphan drug status for ALS-886 in ARDS

Phytopharm advances phase II smilagenin trial in early-stage Parkinson's disease

New GlyT-1 inhibitors claimed by sanofi-aventis

Phase III APPRAISE-2 trial of apixaban in ACS discontinued

Reolysin to enter phase I trial in pediatric patients with solid tumors

FDA approves Xgeva for SRE prophylaxis in patients with bone metastases from solid tumors

Second interim RESTORE-CLI data analysis shows primary endpoints met

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...